Summary
CYP2C8 substrates are compounds that are metabolized by CYP2C8 (a cytochrome P450 enzyme), but do not necessarily affect its activity.
In the presence of CYP2C8 inhibitors or CYP2C8inducers|inducers, the metabolism of CYP2C8 substrates can be affected.
The table below outlines some of the most common or clinically relevant CYP2C8 substrates.[1][2][3] Importantly, this list is not exhaustive.
| CYP2C8 Substrates |
|---|
| Enzalutamide |
| Imatinib |
| Montelukast |
| Paclitaxel |
| Pioglitazone |
| Repaglinide |
| Rosiglitazone |
References
- ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
- ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
- ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)